Skip to main content

On the afternoon of October 16th, BIO will present the first BIO Seed-Stage Spotlight on Tech Transfer, featuring more than two dozen exciting early-stage companies giving brief pitches and getting investor feedback in front of our audience.  All these companies will then participate in the BIO One-on-One Partnering™ system during the BIO Investor Forum. 

To identify this set of start-ups, BIO worked with the following organizations with experience supporting and incubating such innovative entrepreneurs, especially those with ties to academic biomedical research:  California Life Sciences FAST advisory program, SPARK at Stanford, NYU Endless Frontier Labs, Tulane University School of Medicine, UCSF Innovation Ventures, WARF, MBC BioLabs, IndieBio, and Breakout Ventures.

 

DOWNLOAD SCHEDULE   RSVP FOR THIS EVENT

Presentation Schedule

Loading
1:30 PM
  1. Franciscan B
    15 mins
  2. Franciscan C
    15 mins
1:45 PM
  1. Franciscan B
    10 mins
    • Dermatology
    PSOMRI has a targeted drug portfolio against skin inflammation, by combining bioinformatics with biochemical and pharmacokinetic enhancements to enable robust IP. Our lead compound MRI001 is highly po ...
  2. Franciscan C
    10 mins
    • Auditory (Hearing Loss)
    Thirty-six million Americans and hundreds of millions globally currently suffer from hearing loss, a condition with profound health impacts for patients that are responsible for an estimated $122B in ...
1:55 PM
  1. Franciscan B
    10 mins
    • Gastrointestinal
    Azora Therapeutics is a clinical-stage biotechnology company developing potential first-in-class/best-in-class aryl hydrocarbon receptor (AhR) agonists for ulcerative colitis and inflammatory skin dis ...
  2. Franciscan C
    10 mins
    • Digital Health
    We use artificial intelligence to design interventions for optimization of newborn health in neonatal intensive care units. This is based on deep technologies developed at Stanford University.
2:05 PM
  1. Franciscan B
    10 mins
    • Infectious Diseases
    Informuta’s mission is to provide clinicians with precision diagnostics for antibiotic resistant infections using machine learning and our proprietary data analytics platform on next-generation sequen ...
  2. Franciscan C
    10 mins
    • Cardiovascular
    Mitochondria-rich extracellular vesicles (M-EVs) generated from iCMs contain healthy mitochondria and bioactive proteomes. M-EV-mediated mitochondrial transplantation therapy will restore the energy m ...
2:15 PM
  1. Franciscan B
    10 mins
  2. Franciscan C
    10 mins
    • CNS/Neurological
    HDAX Therapeutics is pioneering best-in-class therapeutics for neurological and cardiovascular diseases by targeting the root causes of these diseases. Leveraging our molecular recognition platform te ...
2:25 PM
  1. Franciscan B
    10 mins
    • Inflammation
    Interface Biosciences is an AI-enabled metabolomics-based drug discovery engine. Inflammatory Disease is a huge unmet need. IBD, eczema, and rheumatoid arthritis all have millions of patients with bil ...
  2. Franciscan C
    10 mins
    • CNS/Neurological
    Stem Pharm is a neurologic drug discovery platform company using a human-first approach. Our patented platform is based on human stem cell derived 3D neural models (i.e. brain organoids) that uniquely ...
2:35 PM
  1. Franciscan B
    10 mins
  2. Franciscan C
    10 mins
    • CNS/Neurological
    Acurex Biosciences Corporation is a pharmaceutical company with a mission to halt major neurodegenerative diseases, starting with Parkinson’s disease (PD). Acurex was founded in 2019 based on a Stanfo ...
3:05 PM
  1. Franciscan B
    10 mins
    • Diagnostics
    Invenio is providing instant and highly accurate detection of cancer in tissue biopsies with laser imaging and artificial intelligence. Real-time tissue analysis impacts more than 13 million cancer pa ...
  2. Franciscan C
    10 mins
3:15 PM
  1. Franciscan B
    10 mins
    • Oncology
    At Myka Labs, our mission is to help millions of patients with pancreatic cancer and other challenging conditions live longer, healthier lives. Our Conflux(TM) platform combines advanced artificial in ...
  2. Franciscan C
    10 mins
    • Gene/Cell Therapy
    BrainXell Therapeutics is a regenerative medicine company developing disease-modifying personalized cell therapies, with a focus on neurological indications. BrainXell Therapeutics utilizes proprietar ...
3:25 PM
  1. Franciscan B
    10 mins
    • Oncology
    microMESH is developing a proprietary technology for the controlled, sustained, and deep intratumor delivery of small molecules, antibodies, and RNA-based medicines. The technology, called also microM ...
  2. Franciscan C
    10 mins
    • Gene/Cell Therapy
    Minutia is working on a functional cure for Type 1 Diabetes. Minutia’s subcutaneous transplant of insulin producing cells is delivered through a simple procedure and customized for safety and efficacy ...
3:35 PM
  1. Franciscan B
    10 mins
    Panazee is developing a proprietary point of care diagnostic technology that fully removes background signal with a unique micro-bead washing one step process. This allows Panazee hardware to achieve ...
  2. Franciscan C
    10 mins
    • Ophthalmology
    Developing neuroprotection and regeneration therapies for optic nerve and CNS neurodegenerative diseases
3:45 PM
  1. Franciscan B
    10 mins
    • Oncology
    MEDiC Life Sciences (MEDiC) is a SF Bay Area startup focused on discovering novel drug targets and biomarkers for solid cancers. Their proprietary CRISPR functional genomics platform, using patient-tu ...
  2. Franciscan C
    10 mins
    • Ophthalmology
    ViAn Therapeutics is a visionary virtual pharma startup at the forefront of combating microvascular retinal diseases. Focused on conditions like diabetic retinopathy and age-related macular degenerati ...
4:15 PM
  1. Franciscan B
    10 mins
    • Oncology
    "Enhancing Host-Anti-Tumor Immune Response by Modulation of Tumor-Associated Macrophages" from the SPARK at Stanford program, presented by Dr. Lawrence Leung, Professor of Medicine, Stanford Universit ...
  2. Franciscan C
    10 mins
    • Regenerative Medicine
    Dorian Therapeutics is a YC- and VC-backed preclinical company developing small molecules aimed to reactivate stem cell pathways crucial for tissue regeneration. Focused on targeting key epigenetic re ...
4:25 PM
  1. Franciscan B
    10 mins
    • Oncology
    f5 Therapeutics is a privately held, pharmaceutical company that focuses on targeted protein degradation via ‘molecular glues.’ Our NExMod™ (Neosubstrate Expression Modulators) platform focuses on dis ...
  2. Franciscan C
    10 mins
    • Platform for Therapeutics
    Aluda Pharmaceuticals approaches drug discovery with a deep understanding of biology. Our domain is the signaling between and within cells that is central to immunological defense, inflammation and pa ...
4:35 PM
  1. Franciscan B
    10 mins
    • Oncology
    LynxBio is a tech-enabled biotechnology company leveraging a proprietary ex vivo disease biology platform to generate multi-omic insights to accelerate the discovery and development of next-generation ...
  2. Franciscan C
    10 mins
    • Platform for Therapeutics
    Packaging of the human genome in the form of chromatin is critical for dictating which parts of the genome can be transcribed and which cannot. Cancer biologists have long known that defects in chroma ...
4:45 PM
  1. Franciscan B
    10 mins
    • Oncology
    Lime Therapeutics is creating precision medicines for diseases of lipid dysfunction, including many forms of cancer, neurodegenerative disorders, and metabolic diseases. Borne out of technology develo ...
  2. Franciscan C
    10 mins
    • Platform for Therapeutics
    ProgrammableTx, emerging from MIT and Cornell, is developing mRNA medicines for proteome editing. ProgrammableTx is built on two key pillars: computational design by AI/ML and state-of-the art protein ...
4:55 PM
  1. Franciscan B
    10 mins
    • Oncology
    Sardona Therapeutics is building the leading platform to develop novel precision oncology small molecule drugs that target RNA-binding proteins in the spliceosome and provide patients with therapy-res ...
  2. Franciscan C
    10 mins
    • Platform for Therapeutics
    Recognized as the 2022 Top Emerging Company at the BIO International Convention's Start-Up Stadium, SiVEC Biotechnologies has developed BactPac™, a live biotherapeutic delivery platform to enable the ...
5:05 PM
  1. Franciscan B
    10 mins
    • Oncology
    Laguna Bio is an IND-ready company that makes immunotherapy effective for everyone. We've developed a live bacterial therapeutic that activates and expands endogenous gamma delta T cells. These cells ...
  2. Franciscan C
    10 mins
    • Platform for Therapeutics
    Immuto Scientific is a biotechnology company that is transforming the way biotherapeutics are discovered. Our proprietary platform utilizes structure-based protein analysis to enable the discovery of ...
5:15 PM
  1. Franciscan B
    10 mins
    • Oncology
    Telo Therapeutics is developing a small molecule that is well positioned to become a best in class inhibitor of XPO1, a clinically validated but under-exploited oncology target. The only marketed XPO1 ...
  2. Franciscan C
    10 mins
    • Tools/Drug Development Support Tech
    CellChorus is the leader in performing high‑throughput, dynamic analysis of individual cell behavior, interactions, and function over time to improve the development and delivery of cell‑based product ...
5:30 PM
  1. Grand Ballroom, Grand Ballroom Level, Tower 2
    60 mins

    Please join this reception to meet the day’s presenters for networking with them and other biotechnology colleagues.

BIO DOUBLE HELIX SPONSOR

BIO HELIX SPONSOR

CONFERENCE SPONSORS